The Global Influenza Vaccine Equipment Market is experiencing a remarkable surge, with a projected valuation to reach US$ 51.53 billion by 2032 from US$ 11.43 billion in 2023, growing at a compound annual growth rate (CAGR) of 18.21% during the forecast period from 2024 to 2032.
The global influenza vaccine equipment market is experiencing substantial growth throughout the projected timeframe. This surge in growth is primarily due to the prevalence and occurrence of different strains of influenza viruses, which greatly enhance the demand for vaccine production equipment. Additionally, the continuous advancements in technology pertaining to vaccine production are emerging as a groundbreaking trend in the global market.
The Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/influenza-vaccine-equipment-market
Seasonal influenza epidemics caused by influenza A and B viruses result in 3 to 5 million severe cases and thousands of deaths globally each year. In addition to these seasonal outbreaks, influenza pandemics caused by the influenza A virus can emerge at unpredictable intervals, posing significant public health challenges. Given the high rate of incidence and the severity of influenza-related illnesses and deaths, a robust response in terms of vaccine production is necessary. The World Health Organization (WHO) estimates that annual influenza epidemics result in about 3 to 5 million cases of severe illness and about 290,000 to 650,000 respiratory deaths worldwide.
To mitigate the impact of influenza, the Centers for Disease Control and Prevention (CDC) recommends administering an annual influenza vaccine for all individuals older than six months of age who do not have contraindications. Vaccination is considered the best way to prevent the disease and reduce its severity. The efficacy of the seasonal influenza vaccine can vary each year due to factors such as the match between the circulating viruses and the vaccine strains. The vaccine’s effectiveness typically ranges between 10% and 60%. While the vaccine may not always be completely related to the predominant circulating virus, it can protect against multiple influenza viruses and prevent influenza-related illnesses.
Global Influenza Vaccine Production Skyrockets: Impacting the Global Influenza Vaccine Equipment Market
The global production of influenza vaccines has been steadily increasing to meet the growing demand for immunization. The World Health Organization (WHO) has reported a significant rise in the total number of vaccine doses produced and consumed annually. Specifically, the global production capacity for pandemic influenza vaccines has increased from approximately 1.5 billion doses in 2006 to 6.4 billion doses in 2019.
According to the National Center for Biotechnology Information (NCBI), there has been modest growth in pandemic influenza vaccine production capacity since 2015. Additionally, the estimated annual production of seasonal influenza vaccine capacity stands at 1.48 billion doses. In the best-case scenario, the annual production capacity for pandemic vaccines is likely to reach 8.31 billion doses.
In line with the increasing global production capacity, vaccine manufacturers have projected to supply the United States with a substantial number of influenza vaccine doses for the 2022-2023 season. According to the Centers for Disease Control and Prevention (CDC), they anticipate delivering as many as 173.5 million to 183.5 million doses of influenza vaccines. It is worth noting that all flu vaccines for this season will be quadrivalent, meaning they will contain four components. Furthermore, the majority of these vaccines (93%) will be thimerosal-free or have reduced thimerosal content. Additionally, approximately 20% of the flu vaccines will be egg-free.
In summary, the global production of influenza vaccines has been increasing to meet the rising demand. The production capacity for pandemic and seasonal vaccines has seen steady growth, with projections indicating a significant supply of influenza vaccines to the United States for the upcoming season.
Technological Innovations: A Transformative Trend to Watch
Technological innovations in vaccine production are revolutionizing the global influenza vaccine equipment market. These advancements enhance the efficacy of vaccines and reshape the manufacturing process, thereby influencing the demand and development of production equipment.
One prominent trend showcasing these innovations is the growth of cell-based vaccine production. As of 2021, approximately 20% of influenza vaccines distributed in the United States were produced using cell-based technology. This method, known for its efficiency compared to traditional egg-based methods, is expected to capture a larger market share, with projections indicating an annual growth rate of about 8%.
Investments in alternative production methods, such as recombinant DNA technology, further highlight this transformative trend. The recombinant influenza vaccine market, although currently a smaller segment, is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of approximately 6.5% from 2020 to 2025. This technology enables faster and more flexible vaccine production, which is crucial in responding to emerging influenza strains.
The integration of artificial intelligence (AI) and machine learning in vaccine development is another pivotal aspect of this trend. By 2025, AI in the healthcare market is likely to reach US$ 36.1 billion, with a significant portion allocated to vaccine research and development. AI plays a crucial role in predicting influenza virus evolution and selecting appropriate vaccine strains.
Additionally, investments in research and development for mRNA-based influenza vaccines have surged following the COVID-19 pandemic. Companies like Pfizer and Moderna, having successfully developed mRNA COVID-19 vaccines, are now directing their efforts toward similar technology for influenza. Moderna, for instance, plans to commence clinical trials for its mRNA flu vaccine in 2021.
North America Accounts for 37% of Market Revenue Share
North America is at the forefront of the global influenza vaccine equipment market, holding more than 37% of the market share. This region’s advanced healthcare infrastructure, high public health awareness, and significant government funding drive robust market growth.
In the United States, the Centers for Disease Control and Prevention (CDC) plays a pivotal role in influenza prevention, contributing to the heightened demand for vaccine production equipment. The U.S. witnesses substantial annual spending on healthcare research and development (R&D), further propelling the market.
The demand for influenza vaccines in the U.S. is substantial. For the 2022-2023 season, vaccine manufacturers have projected to supply the United States with as many as 173.5 million to 183.5 million doses of influenza vaccines. These vaccines will be quadrivalent (four-component), with the majority being thimerosal-free or thimerosal-reduced and about 20% being egg-free.
It is worth noting that healthcare spending in the United States is higher compared to other high-income countries. In 2021, the U.S. national healthcare expenditure reached US$ 4.3 trillion, or US$ 12,914 per person, and is estimated to reach US$ 6.2 trillion by 2028. The U.S. spent nearly 16.8% of its gross domestic product (GDP) on healthcare in 2019.
Technological innovations in vaccine production are transforming the global influenza vaccine equipment market. One notable trend is the growth in the cell-based vaccine production segment. As of 2021, approximately 20% of the influenza vaccines distributed in the U.S. were produced using cell-based technology. This method is considered more efficient than traditional egg-based methods and is likely to account for the largest market share, with projections indicating an annual growth rate of approximately 8%.
For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/influenza-vaccine-equipment-market
Investment in alternative production methods, such as recombinant DNA technology, is driving market growth. The recombinant influenza vaccine market, though currently a smaller segment, is growing rapidly, with a projected compound annual growth rate (CAGR) of about 6.5% from 2020 to 2025. This technology enables faster and more flexible vaccine production, which is crucial in responding to emerging influenza strains.
Furthermore, the adoption of artificial intelligence (AI) and machine learning in vaccine development is playing a pivotal role. AI is increasingly being used to predict influenza virus evolution and aid in vaccine strain selection. By 2025, AI in the healthcare market is anticipated to reach US$ 36.1 billion, with a significant portion directed towards vaccine research and development.
Top Players in the Global Influenza Vaccine Equipment Market
- ALFA LAVAL
- BIOTECHNO Ltd
- EMCOR Group Inc.
- Eppendorf Himac Technologies Co.
- Esco VacciXcell
- Hitachi Koki (Koki Holdings Co., Ltd.)
- ITT Engineered Valves
- MGA Technologies
- Microfluidics International Corporation
- Shikoku Instrumentation CO., LTD.
- Other Prominent Players
Market Segmentation Overview:
- Filtration 000′ Units
- Egg Inspection Devices
- Specialized Ultracentrifuges
- Filling Machine
- Storage And Transfer Reactors
By End User
- Pharmaceutical & Biotechnology Companies
- Medical & Research Institutes
- North America
- The U.S.
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific
- Australia & New Zealand
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Rest of South America
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/influenza-vaccine-equipment-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/